Відмінності між версіями «Le illness in peripheral blood or bone marrow even when»
м |
м |
||
| Рядок 1: | Рядок 1: | ||
| − | + | Santacruz et al.deletion possess a larger probability of remaining MRD-positive immediately after therapy compared to patients without having this chromosome abnormality.18 For all these motives, present guidelines for the management of patients with CLL suggest MRD assessment only inside clinical trials with "curative intention".36 With all this information in mind, we retrospectively evaluated the impact of MRD on the outcome of sufferers with CLL getting any front-line therapy in the context of a really detailed prognostic evaluation, like recently [http://kupon123.com/members/summer3lamb/activity/156443/ . The -PrPase produces membrane-attached C1 and soluble N1 fragments. C1 plays] described recurrent gene mutations.survival and general survival had been calculated utilizing a landmark evaluation. These patients are viewed as to possess achieved a minimal residual illness (MRD) negative status.17-20 Many phase II trials have demonstrated that patients reaching MRD negativity possess a signif-icantly longer survival than people who stay MRD optimistic, and that is accurate for sufferers treated with traditional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) not too long ago revealed that sufferers obtaining MRD negativity had considerably longer progression-free and all round survivals, irrespectively of your remedy received.18 Unfortunately, even so, some of these studies were flawed by inappropriate statistical evaluation, specifically the measurement of time-to-event outcomes from treatment initiation.27 Moreover, there are several caveats for the use of MRD evaluation in individuals with CLL.28 1st, CLL remains incurable and at the least 30 of individuals who obtain MRD negativity immediately after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC eventually expertise a illness relapse inside five years.18 Secondly, as opposed to the circumstance in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is no formal proof of a therapeutic advantage of re-treatment upon documentation of MRD positivity after an initial MRD-negative response compared to remedy in the time of clinical relapse. In actual fact, incredibly couple of research have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and a few with the techniques tested, though helpful, resulted in significant toxicity.33-35 Thirdly, it could possibly be argued that MRD assessment is basically a surrogate for evalution of other adverse prognostic markers because, as an illustration, individuals using a 17p014 Ferrata Storti Foundation. That is an open-access paper. doi:ten.3324/haematol.2013.099796 The on the net version of this short article includes a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(five)R. Santacruz et al.deletion have a larger probability of remaining MRD-positive following therapy in comparison to patients without having this chromosome abnormality.18 For all these motives, existing guidelines for the management of patients with CLL advise MRD assessment only inside clinical trials with "curative intention".36 With all this details in mind, we retrospectively evaluated the influence of MRD on the outcome of patients with CLL receiving any front-line therapy within the context of a really detailed prognostic evaluation, including not too long ago described recurrent gene mutations.survival and all round survival have been calculated using a landmark evaluation. All calculations had been performed working with either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 have been regarded statistically important. A detailed explanation of your statistical methods is out there in the On line Supplement.Outcomes Baseline characteristicsThe median age from the entire cohort was 58 years (variety, 27-93 years), and also the percentage of patients older than 70 years was 22 . As outlined by D ner's hierarchical model, 17/221 (8 ) and 40/221 (18 ) individuals had 17p deletion and 11q deletion, respectively. | |
Версія за 18:59, 24 січня 2018
Santacruz et al.deletion possess a larger probability of remaining MRD-positive immediately after therapy compared to patients without having this chromosome abnormality.18 For all these motives, present guidelines for the management of patients with CLL suggest MRD assessment only inside clinical trials with "curative intention".36 With all this information in mind, we retrospectively evaluated the impact of MRD on the outcome of sufferers with CLL getting any front-line therapy in the context of a really detailed prognostic evaluation, like recently . The -PrPase produces membrane-attached C1 and soluble N1 fragments. C1 plays described recurrent gene mutations.survival and general survival had been calculated utilizing a landmark evaluation. These patients are viewed as to possess achieved a minimal residual illness (MRD) negative status.17-20 Many phase II trials have demonstrated that patients reaching MRD negativity possess a signif-icantly longer survival than people who stay MRD optimistic, and that is accurate for sufferers treated with traditional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) not too long ago revealed that sufferers obtaining MRD negativity had considerably longer progression-free and all round survivals, irrespectively of your remedy received.18 Unfortunately, even so, some of these studies were flawed by inappropriate statistical evaluation, specifically the measurement of time-to-event outcomes from treatment initiation.27 Moreover, there are several caveats for the use of MRD evaluation in individuals with CLL.28 1st, CLL remains incurable and at the least 30 of individuals who obtain MRD negativity immediately after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC eventually expertise a illness relapse inside five years.18 Secondly, as opposed to the circumstance in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is no formal proof of a therapeutic advantage of re-treatment upon documentation of MRD positivity after an initial MRD-negative response compared to remedy in the time of clinical relapse. In actual fact, incredibly couple of research have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and a few with the techniques tested, though helpful, resulted in significant toxicity.33-35 Thirdly, it could possibly be argued that MRD assessment is basically a surrogate for evalution of other adverse prognostic markers because, as an illustration, individuals using a 17p014 Ferrata Storti Foundation. That is an open-access paper. doi:ten.3324/haematol.2013.099796 The on the net version of this short article includes a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(five)R. Santacruz et al.deletion have a larger probability of remaining MRD-positive following therapy in comparison to patients without having this chromosome abnormality.18 For all these motives, existing guidelines for the management of patients with CLL advise MRD assessment only inside clinical trials with "curative intention".36 With all this details in mind, we retrospectively evaluated the influence of MRD on the outcome of patients with CLL receiving any front-line therapy within the context of a really detailed prognostic evaluation, including not too long ago described recurrent gene mutations.survival and all round survival have been calculated using a landmark evaluation. All calculations had been performed working with either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 have been regarded statistically important. A detailed explanation of your statistical methods is out there in the On line Supplement.Outcomes Baseline characteristicsThe median age from the entire cohort was 58 years (variety, 27-93 years), and also the percentage of patients older than 70 years was 22 . As outlined by D ner's hierarchical model, 17/221 (8 ) and 40/221 (18 ) individuals had 17p deletion and 11q deletion, respectively.
